Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
Avelo Airlines to End DHS Deportation Flights and Close Arizona Base Amid Rising Costs 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
Embraer Boosts Aircraft Deliveries in Q4 2025, Signaling Strong Growth Into 2026 
China Reviews Meta’s $2 Billion AI Deal With Manus Amid Technology Control Concerns 
Barclays Invests in Stablecoin Clearing Firm Ubyx to Advance Digital Money Strategy 
AMD Unveils Next-Generation AI and PC Chips at CES, Highlights Major OpenAI Partnership 
Jollibee Plans U.S. Listing for International Business, Shares Rally 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
Newmont Goldcorp Expects Lower Q1 2026 Gold Output After Western Australia Bushfire 
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations 
Baidu’s AI Chip Unit Kunlunxin Prepares for Hong Kong IPO to Raise Up to $2 Billion 
TEMPLE CITY, Calif., Oct. 24, 2017 -- Fulgent Genetics, Inc. (NASDAQ:FLGT) (“Fulgent Genetics” or the “company”) today announced that its Chairman and Chief Executive Officer Ming Hsieh and its Chief Financial Officer Paul Kim are scheduled to participate in the 2017 Credit Suisse Annual Healthcare Conference on Tuesday, November 7, 2017 at The Phoenician in Scottsdale, Arizona.
At the conference, these representatives of the company will participate in a series of one-on-one meetings, which will not be webcast.
About Fulgent Genetics
Fulgent Genetics is a growing technology company with an initial focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the quality of patient care. The company has developed a proprietary technology platform that integrates sophisticated data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. This platform allows the company to offer a broad and flexible test menu and continually expand and improve its proprietary genetic reference library, while maintaining accessible pricing, high accuracy and competitive turnaround times. The company believes its current test menu, which includes approximately 18,000 single-gene tests and more than 850 pre-established, multi-gene, disease-specific panels, offers more genes for testing than its competitors in today’s market, which enables it to provide expansive options for test customization and clinically actionable results.
Investor Relations Contacts:
The Blueshirt Group
Nicole Borsje, 415-217-2633, [email protected]
Chris Danne, 415-217-5865, [email protected]
